R&D Productivity: Not So Bad After All?

Falling Big Pharma R&D productivity is often cited as the industry's Achilles heel. Yet simply counting the number of drug launches each year versus R&D spend doesn't give a true picture of the industry's productivity, argue analysts at CSFB. Productivity is not falling, they say, but gains just aren't visible yet. In five years, large pharmaceutical companies-particularly those in Europe-may emerge from this fog with renewed strength.

Most observers blame declining R&D productivity—bigger spending, fewer results—for the drug industry's woes. The latest estimates from industry consultants Bain & Co. put the cost of developing a new drug at $1.7 billion, largely due to an increasing number of clinical failures. (See "Rebuilding Big Pharma's Business Model," IN VIVO, November 2003 Also see "Rebuilding Big Pharma's Business Model" - In Vivo, 1 November, 2003..) Average return on investment: about 5%, lower than the cost of capital.

But analysts at CSFB in London argue that this view of R&D productivity oversimplifies the issues and obscures the reality...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.